Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Elan Moving Alzheimer’s Candidate To Phase II Under Pact With Transition Therapeutics

This article was originally published in The Pink Sheet Daily

Executive Summary

Initial terms of the partnership include an unusual 70/30 split on development costs and eventual profits.

You may also be interested in...



Lilly Acquires Diabetes Candidates In Deal With Transition Therapeutics

After ending its efforts to develop inhaled insulin, Lilly rebuilds in-house pipeline of diabetes candidates.

Lilly Acquires Diabetes Candidates In Deal With Transition Therapeutics

After ending its efforts to develop inhaled insulin, Lilly rebuilds in-house pipeline of diabetes candidates.

Samaritan Moves Development of Caprospinol Ahead Through Advinus Deal

The company plans to run extensive preclinical studies evaluating the Alzheimer’s candidate, then enter Phase I trials by the end of the year.

Related Content

Topics

UsernamePublicRestriction

Register

PS064940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel